Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $7.50 USD
Change Today +0.48 / 6.84%
Volume 1.0K
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

elekta ab-b shs (EKTAF) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/4/14 - $13.05
52 Week Low
05/19/15 - $6.99
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ELEKTA AB-B SHS (EKTAF)

Related News

No related news articles were found.

elekta ab-b shs (EKTAF) Related Businessweek News

No Related Businessweek News Found

elekta ab-b shs (EKTAF) Details

Elekta AB (publ), develops and sells clinical solutions for the treatment of cancer and brain disorders worldwide. The company offers Leksell Gamma Knife, a system for cranial stereotactic radiosurgery; the Extend sytem for utilization of Leksell Gamma Knife Perfexion; and Leksell Stereotactic System for neurosurgery and biopsies. Its neuroscience solutions comprise Gamma Knife radiosurgery for the treatment of brain disorders; stereotactic neurosurgery; and surgical navigation accessories, as well as Elekta Neuromag TRIUX, a magnetoencephalography platform. The company also provides oncology treatment solutions, such as Precise Treatment System, a digital treatment system; Elekta Axesse, a stereotactic radiation therapy system; Elekta Compact, a gateway to RT for oncology centers; Elekta Synergy system that visualize tumor targets and normal tissue, and their movement between and during fractions; treatment planning systems; oncology information systems solutions; Versa HD, a linear accelerator; and Elekta Infinity system for volumetric arc modulated therapy, as well as various treatment techniques. In addition, it offers brachytherapy solutions that include afterloading platforms; real-time prostate solutions; Oncentra Brachy, a radiotherapy treatment planning system; Esteya for treating skin cancer; and applicators. Further, the company provides software products, including MOSAIQ oncology information system; Oncology Informatics/Data Alliances that streamlines the flow of information in the cancer care team; medical oncology software; Clarity Soft Tissue Visualization, a software for radiation therapy; and METRIQ, a cancer registry data solution. It also offers installation and implementation, service and support, remote, upgrades and accessories, and financial solutions, as well as training, education, and consultative services. It primarily serves hospitals and academic institutions. The company was founded in 1972 and is headquartered in Stockholm, Sweden.

3,802 Employees
Last Reported Date: 03/4/15
Founded in 1972

elekta ab-b shs (EKTAF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

elekta ab-b shs (EKTAF) Key Developments

Elekta AB, Q4 2015 Earnings Call, May 13, 2015

Elekta AB, Q4 2015 Earnings Call, May 13, 2015

Elekta Announces Management Changes

Elekta announced that Niklas Savander has, with immediate effect, stepped down from his position as President and CEO of the company. The Board of Directors has appointed Tomas Puusepp as President and CEO as of May 13, 2015. Tomas Puusepp is currently Executive Director of the Elekta Board and served as President and CEO of Elekta during fiscal years 2006 to 2014.

Elekta Announces Preliminary Earnings Results for the Year Ended April 2015; Provides Earnings Guidance for the Fiscal Year 2015

Elekta announced preliminary earnings results for the year ended April 2015. For the year, preliminary net sales amounted to SEK 10,800 million compared to SEK 10,694 million, equivalent to an increase of 1%. Based on constant exchange rates the decrease was 8%. Preliminary cash flow after continuous investments amounted to approximately SEK 800 million compared to SEK 494 million a year ago. The improvement mainly came from a reduction in working capital. The company’s results for the fourth quarter and the full year were significantly below expectations and the guidance given. This was primarily due to weak performance in the US. Large orders did not close as anticipated. Results were also impacted by delays in deliveries from order backlog, particularly in emerging markets, due to market conditions, political developments, war and civil unrest. Preliminary EBITA, before non-recurring items, for fiscal year 2014-2015 is expected to be approximately SEK 1,400 million, negatively affected mainly by the decrease in net sales.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EKTAF:US $7.50 USD +0.48

EKTAF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Accuray Inc $6.15 USD +0.02
Eckert-Ziegler Bebig €1.34 EUR 0.00
Icad Inc $4.95 USD +0.10
MRI Interventions Inc $1.01 USD -0.009
RaySearch Laboratories AB kr113.00 SEK +3.00
View Industry Companies

Industry Analysis


Industry Average

Valuation EKTAF Industry Range
Price/Earnings 22.7x
Price/Sales 2.1x
Price/Book 3.7x
Price/Cash Flow 21.7x
TEV/Sales 1.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELEKTA AB-B SHS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at